Clinical Implementation of MicroRNAs in Cancer Immunology

MicroRNAs (miRNAs), or small non-coding RNAs, modulate the expression of mRNAs and, consequently, a variety of signal transduction pathways. Due to their dysregulation in cancer, they exert oncogenic pressure and have an impact on the immune system with their protective functions. These immunosuppre...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Heidi Schwarzenbach [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2024

Schlagwörter:	immune system T cells dendritic cells macrophages miRNAs signal transduction pathways

Übergeordnetes Werk:	In: International Journal of Translational Medicine - MDPI AG, 2021, 4(2024), 1, Seite 53-71
Übergeordnetes Werk:	volume:4 ; year:2024 ; number:1 ; pages:53-71

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.3390/ijtm4010003

Katalog-ID:	DOAJ100490840

Internformat


LEADER	01000naa a22002652 4500
001	DOAJ100490840
003	DE-627
005	20240414095959.0
007	cr uuu---uuuuu
008	240414s2024 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.3390/ijtm4010003 \|2 doi
035			\|a (DE-627)DOAJ100490840
035			\|a (DE-599)DOAJc06fc88e1ce14363a2cf1ba9caee5d7c
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a R858-859.7
100	0		\|a Heidi Schwarzenbach \|e verfasserin \|4 aut
245	1	0	\|a Clinical Implementation of MicroRNAs in Cancer Immunology
264		1	\|c 2024
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a MicroRNAs (miRNAs), or small non-coding RNAs, modulate the expression of mRNAs and, consequently, a variety of signal transduction pathways. Due to their dysregulation in cancer, they exert oncogenic pressure and have an impact on the immune system with their protective functions. These immunosuppressive characteristics of miRNAs in cancer promote cancer progression and metastasis, causing the dysregulation of immune cells and the immune escape of tumor cells. In contrast, there are also tumor suppressor miRNAs that are able to activate the immune system. Therefore, studies on the altered expression of miRNAs that consider both the oncogenic and tumor-suppressive aspects of miRNAs have become an important research field for advancing immunotherapeutic interventions using miRNAs or their inhibitors as therapeutics. In the current review, their potential in the immunomodulation of immune cells and their use as immune stimulatory molecules to elicit specific cytotoxic responses against the tumor are discussed.
650		4	\|a immune system
650		4	\|a T cells
650		4	\|a dendritic cells
650		4	\|a macrophages
650		4	\|a miRNAs
650		4	\|a signal transduction pathways
653		0	\|a Computer applications to medicine. Medical informatics
773	0	8	\|i In \|t International Journal of Translational Medicine \|d MDPI AG, 2021 \|g 4(2024), 1, Seite 53-71 \|w (DE-627)178364026X \|x 26738937 \|7 nnns
773	1	8	\|g volume:4 \|g year:2024 \|g number:1 \|g pages:53-71
856	4	0	\|u https://doi.org/10.3390/ijtm4010003 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/c06fc88e1ce14363a2cf1ba9caee5d7c \|z kostenfrei
856	4	0	\|u https://www.mdpi.com/2673-8937/4/1/3 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2673-8937 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_39
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 4 \|j 2024 \|e 1 \|h 53-71

Indexfelder

author_variant	h s hs
matchkey_str	article:26738937:2024----::lnclmlmnainfirraic
hierarchy_sort_str	2024
callnumber-subject-code	R
publishDate	2024
allfields	10.3390/ijtm4010003 doi (DE-627)DOAJ100490840 (DE-599)DOAJc06fc88e1ce14363a2cf1ba9caee5d7c DE-627 ger DE-627 rakwb eng R858-859.7 Heidi Schwarzenbach verfasserin aut Clinical Implementation of MicroRNAs in Cancer Immunology 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier MicroRNAs (miRNAs), or small non-coding RNAs, modulate the expression of mRNAs and, consequently, a variety of signal transduction pathways. Due to their dysregulation in cancer, they exert oncogenic pressure and have an impact on the immune system with their protective functions. These immunosuppressive characteristics of miRNAs in cancer promote cancer progression and metastasis, causing the dysregulation of immune cells and the immune escape of tumor cells. In contrast, there are also tumor suppressor miRNAs that are able to activate the immune system. Therefore, studies on the altered expression of miRNAs that consider both the oncogenic and tumor-suppressive aspects of miRNAs have become an important research field for advancing immunotherapeutic interventions using miRNAs or their inhibitors as therapeutics. In the current review, their potential in the immunomodulation of immune cells and their use as immune stimulatory molecules to elicit specific cytotoxic responses against the tumor are discussed. immune system T cells dendritic cells macrophages miRNAs signal transduction pathways Computer applications to medicine. Medical informatics In International Journal of Translational Medicine MDPI AG, 2021 4(2024), 1, Seite 53-71 (DE-627)178364026X 26738937 nnns volume:4 year:2024 number:1 pages:53-71 https://doi.org/10.3390/ijtm4010003 kostenfrei https://doaj.org/article/c06fc88e1ce14363a2cf1ba9caee5d7c kostenfrei https://www.mdpi.com/2673-8937/4/1/3 kostenfrei https://doaj.org/toc/2673-8937 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_39 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2024 1 53-71
spelling	10.3390/ijtm4010003 doi (DE-627)DOAJ100490840 (DE-599)DOAJc06fc88e1ce14363a2cf1ba9caee5d7c DE-627 ger DE-627 rakwb eng R858-859.7 Heidi Schwarzenbach verfasserin aut Clinical Implementation of MicroRNAs in Cancer Immunology 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier MicroRNAs (miRNAs), or small non-coding RNAs, modulate the expression of mRNAs and, consequently, a variety of signal transduction pathways. Due to their dysregulation in cancer, they exert oncogenic pressure and have an impact on the immune system with their protective functions. These immunosuppressive characteristics of miRNAs in cancer promote cancer progression and metastasis, causing the dysregulation of immune cells and the immune escape of tumor cells. In contrast, there are also tumor suppressor miRNAs that are able to activate the immune system. Therefore, studies on the altered expression of miRNAs that consider both the oncogenic and tumor-suppressive aspects of miRNAs have become an important research field for advancing immunotherapeutic interventions using miRNAs or their inhibitors as therapeutics. In the current review, their potential in the immunomodulation of immune cells and their use as immune stimulatory molecules to elicit specific cytotoxic responses against the tumor are discussed. immune system T cells dendritic cells macrophages miRNAs signal transduction pathways Computer applications to medicine. Medical informatics In International Journal of Translational Medicine MDPI AG, 2021 4(2024), 1, Seite 53-71 (DE-627)178364026X 26738937 nnns volume:4 year:2024 number:1 pages:53-71 https://doi.org/10.3390/ijtm4010003 kostenfrei https://doaj.org/article/c06fc88e1ce14363a2cf1ba9caee5d7c kostenfrei https://www.mdpi.com/2673-8937/4/1/3 kostenfrei https://doaj.org/toc/2673-8937 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_39 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2024 1 53-71
allfields_unstemmed	10.3390/ijtm4010003 doi (DE-627)DOAJ100490840 (DE-599)DOAJc06fc88e1ce14363a2cf1ba9caee5d7c DE-627 ger DE-627 rakwb eng R858-859.7 Heidi Schwarzenbach verfasserin aut Clinical Implementation of MicroRNAs in Cancer Immunology 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier MicroRNAs (miRNAs), or small non-coding RNAs, modulate the expression of mRNAs and, consequently, a variety of signal transduction pathways. Due to their dysregulation in cancer, they exert oncogenic pressure and have an impact on the immune system with their protective functions. These immunosuppressive characteristics of miRNAs in cancer promote cancer progression and metastasis, causing the dysregulation of immune cells and the immune escape of tumor cells. In contrast, there are also tumor suppressor miRNAs that are able to activate the immune system. Therefore, studies on the altered expression of miRNAs that consider both the oncogenic and tumor-suppressive aspects of miRNAs have become an important research field for advancing immunotherapeutic interventions using miRNAs or their inhibitors as therapeutics. In the current review, their potential in the immunomodulation of immune cells and their use as immune stimulatory molecules to elicit specific cytotoxic responses against the tumor are discussed. immune system T cells dendritic cells macrophages miRNAs signal transduction pathways Computer applications to medicine. Medical informatics In International Journal of Translational Medicine MDPI AG, 2021 4(2024), 1, Seite 53-71 (DE-627)178364026X 26738937 nnns volume:4 year:2024 number:1 pages:53-71 https://doi.org/10.3390/ijtm4010003 kostenfrei https://doaj.org/article/c06fc88e1ce14363a2cf1ba9caee5d7c kostenfrei https://www.mdpi.com/2673-8937/4/1/3 kostenfrei https://doaj.org/toc/2673-8937 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_39 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2024 1 53-71
allfieldsGer	10.3390/ijtm4010003 doi (DE-627)DOAJ100490840 (DE-599)DOAJc06fc88e1ce14363a2cf1ba9caee5d7c DE-627 ger DE-627 rakwb eng R858-859.7 Heidi Schwarzenbach verfasserin aut Clinical Implementation of MicroRNAs in Cancer Immunology 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier MicroRNAs (miRNAs), or small non-coding RNAs, modulate the expression of mRNAs and, consequently, a variety of signal transduction pathways. Due to their dysregulation in cancer, they exert oncogenic pressure and have an impact on the immune system with their protective functions. These immunosuppressive characteristics of miRNAs in cancer promote cancer progression and metastasis, causing the dysregulation of immune cells and the immune escape of tumor cells. In contrast, there are also tumor suppressor miRNAs that are able to activate the immune system. Therefore, studies on the altered expression of miRNAs that consider both the oncogenic and tumor-suppressive aspects of miRNAs have become an important research field for advancing immunotherapeutic interventions using miRNAs or their inhibitors as therapeutics. In the current review, their potential in the immunomodulation of immune cells and their use as immune stimulatory molecules to elicit specific cytotoxic responses against the tumor are discussed. immune system T cells dendritic cells macrophages miRNAs signal transduction pathways Computer applications to medicine. Medical informatics In International Journal of Translational Medicine MDPI AG, 2021 4(2024), 1, Seite 53-71 (DE-627)178364026X 26738937 nnns volume:4 year:2024 number:1 pages:53-71 https://doi.org/10.3390/ijtm4010003 kostenfrei https://doaj.org/article/c06fc88e1ce14363a2cf1ba9caee5d7c kostenfrei https://www.mdpi.com/2673-8937/4/1/3 kostenfrei https://doaj.org/toc/2673-8937 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_39 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2024 1 53-71
allfieldsSound	10.3390/ijtm4010003 doi (DE-627)DOAJ100490840 (DE-599)DOAJc06fc88e1ce14363a2cf1ba9caee5d7c DE-627 ger DE-627 rakwb eng R858-859.7 Heidi Schwarzenbach verfasserin aut Clinical Implementation of MicroRNAs in Cancer Immunology 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier MicroRNAs (miRNAs), or small non-coding RNAs, modulate the expression of mRNAs and, consequently, a variety of signal transduction pathways. Due to their dysregulation in cancer, they exert oncogenic pressure and have an impact on the immune system with their protective functions. These immunosuppressive characteristics of miRNAs in cancer promote cancer progression and metastasis, causing the dysregulation of immune cells and the immune escape of tumor cells. In contrast, there are also tumor suppressor miRNAs that are able to activate the immune system. Therefore, studies on the altered expression of miRNAs that consider both the oncogenic and tumor-suppressive aspects of miRNAs have become an important research field for advancing immunotherapeutic interventions using miRNAs or their inhibitors as therapeutics. In the current review, their potential in the immunomodulation of immune cells and their use as immune stimulatory molecules to elicit specific cytotoxic responses against the tumor are discussed. immune system T cells dendritic cells macrophages miRNAs signal transduction pathways Computer applications to medicine. Medical informatics In International Journal of Translational Medicine MDPI AG, 2021 4(2024), 1, Seite 53-71 (DE-627)178364026X 26738937 nnns volume:4 year:2024 number:1 pages:53-71 https://doi.org/10.3390/ijtm4010003 kostenfrei https://doaj.org/article/c06fc88e1ce14363a2cf1ba9caee5d7c kostenfrei https://www.mdpi.com/2673-8937/4/1/3 kostenfrei https://doaj.org/toc/2673-8937 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_39 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 4 2024 1 53-71
language	English
source	In International Journal of Translational Medicine 4(2024), 1, Seite 53-71 volume:4 year:2024 number:1 pages:53-71
sourceStr	In International Journal of Translational Medicine 4(2024), 1, Seite 53-71 volume:4 year:2024 number:1 pages:53-71
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	immune system T cells dendritic cells macrophages miRNAs signal transduction pathways Computer applications to medicine. Medical informatics
isfreeaccess_bool	true
container_title	International Journal of Translational Medicine
authorswithroles_txt_mv	Heidi Schwarzenbach @@aut@@
publishDateDaySort_date	2024-01-01T00:00:00Z
hierarchy_top_id	178364026X
id	DOAJ100490840
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ100490840</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414095959.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240414s2024 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/ijtm4010003</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ100490840</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJc06fc88e1ce14363a2cf1ba9caee5d7c</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R858-859.7</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Heidi Schwarzenbach</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Clinical Implementation of MicroRNAs in Cancer Immunology</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2024</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">MicroRNAs (miRNAs), or small non-coding RNAs, modulate the expression of mRNAs and, consequently, a variety of signal transduction pathways. Due to their dysregulation in cancer, they exert oncogenic pressure and have an impact on the immune system with their protective functions. These immunosuppressive characteristics of miRNAs in cancer promote cancer progression and metastasis, causing the dysregulation of immune cells and the immune escape of tumor cells. In contrast, there are also tumor suppressor miRNAs that are able to activate the immune system. Therefore, studies on the altered expression of miRNAs that consider both the oncogenic and tumor-suppressive aspects of miRNAs have become an important research field for advancing immunotherapeutic interventions using miRNAs or their inhibitors as therapeutics. In the current review, their potential in the immunomodulation of immune cells and their use as immune stimulatory molecules to elicit specific cytotoxic responses against the tumor are discussed.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immune system</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">T cells</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">dendritic cells</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">macrophages</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">miRNAs</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">signal transduction pathways</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Computer applications to medicine. Medical informatics</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">International Journal of Translational Medicine</subfield><subfield code="d">MDPI AG, 2021</subfield><subfield code="g">4(2024), 1, Seite 53-71</subfield><subfield code="w">(DE-627)178364026X</subfield><subfield code="x">26738937</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:4</subfield><subfield code="g">year:2024</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:53-71</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/ijtm4010003</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/c06fc88e1ce14363a2cf1ba9caee5d7c</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2673-8937/4/1/3</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2673-8937</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">4</subfield><subfield code="j">2024</subfield><subfield code="e">1</subfield><subfield code="h">53-71</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Heidi Schwarzenbach
spellingShingle	Heidi Schwarzenbach misc R858-859.7 misc immune system misc T cells misc dendritic cells misc macrophages misc miRNAs misc signal transduction pathways misc Computer applications to medicine. Medical informatics Clinical Implementation of MicroRNAs in Cancer Immunology
authorStr	Heidi Schwarzenbach
ppnlink_with_tag_str_mv	@@773@@(DE-627)178364026X
format	electronic Article
delete_txt_mv	keep
author_role	aut
collection	DOAJ
remote_str	true
callnumber-label	R858-859
illustrated	Not Illustrated
issn	26738937
topic_title	R858-859.7 Clinical Implementation of MicroRNAs in Cancer Immunology immune system T cells dendritic cells macrophages miRNAs signal transduction pathways
topic	misc R858-859.7 misc immune system misc T cells misc dendritic cells misc macrophages misc miRNAs misc signal transduction pathways misc Computer applications to medicine. Medical informatics
topic_unstemmed	misc R858-859.7 misc immune system misc T cells misc dendritic cells misc macrophages misc miRNAs misc signal transduction pathways misc Computer applications to medicine. Medical informatics
topic_browse	misc R858-859.7 misc immune system misc T cells misc dendritic cells misc macrophages misc miRNAs misc signal transduction pathways misc Computer applications to medicine. Medical informatics
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	International Journal of Translational Medicine
hierarchy_parent_id	178364026X
hierarchy_top_title	International Journal of Translational Medicine
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)178364026X
title	Clinical Implementation of MicroRNAs in Cancer Immunology
ctrlnum	(DE-627)DOAJ100490840 (DE-599)DOAJc06fc88e1ce14363a2cf1ba9caee5d7c
title_full	Clinical Implementation of MicroRNAs in Cancer Immunology
author_sort	Heidi Schwarzenbach
journal	International Journal of Translational Medicine
journalStr	International Journal of Translational Medicine
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2024
contenttype_str_mv	txt
container_start_page	53
author_browse	Heidi Schwarzenbach
container_volume	4
class	R858-859.7
format_se	Elektronische Aufsätze
author-letter	Heidi Schwarzenbach
doi_str_mv	10.3390/ijtm4010003
title_sort	clinical implementation of micrornas in cancer immunology
callnumber	R858-859.7
title_auth	Clinical Implementation of MicroRNAs in Cancer Immunology
abstract	MicroRNAs (miRNAs), or small non-coding RNAs, modulate the expression of mRNAs and, consequently, a variety of signal transduction pathways. Due to their dysregulation in cancer, they exert oncogenic pressure and have an impact on the immune system with their protective functions. These immunosuppressive characteristics of miRNAs in cancer promote cancer progression and metastasis, causing the dysregulation of immune cells and the immune escape of tumor cells. In contrast, there are also tumor suppressor miRNAs that are able to activate the immune system. Therefore, studies on the altered expression of miRNAs that consider both the oncogenic and tumor-suppressive aspects of miRNAs have become an important research field for advancing immunotherapeutic interventions using miRNAs or their inhibitors as therapeutics. In the current review, their potential in the immunomodulation of immune cells and their use as immune stimulatory molecules to elicit specific cytotoxic responses against the tumor are discussed.
abstractGer	MicroRNAs (miRNAs), or small non-coding RNAs, modulate the expression of mRNAs and, consequently, a variety of signal transduction pathways. Due to their dysregulation in cancer, they exert oncogenic pressure and have an impact on the immune system with their protective functions. These immunosuppressive characteristics of miRNAs in cancer promote cancer progression and metastasis, causing the dysregulation of immune cells and the immune escape of tumor cells. In contrast, there are also tumor suppressor miRNAs that are able to activate the immune system. Therefore, studies on the altered expression of miRNAs that consider both the oncogenic and tumor-suppressive aspects of miRNAs have become an important research field for advancing immunotherapeutic interventions using miRNAs or their inhibitors as therapeutics. In the current review, their potential in the immunomodulation of immune cells and their use as immune stimulatory molecules to elicit specific cytotoxic responses against the tumor are discussed.
abstract_unstemmed	MicroRNAs (miRNAs), or small non-coding RNAs, modulate the expression of mRNAs and, consequently, a variety of signal transduction pathways. Due to their dysregulation in cancer, they exert oncogenic pressure and have an impact on the immune system with their protective functions. These immunosuppressive characteristics of miRNAs in cancer promote cancer progression and metastasis, causing the dysregulation of immune cells and the immune escape of tumor cells. In contrast, there are also tumor suppressor miRNAs that are able to activate the immune system. Therefore, studies on the altered expression of miRNAs that consider both the oncogenic and tumor-suppressive aspects of miRNAs have become an important research field for advancing immunotherapeutic interventions using miRNAs or their inhibitors as therapeutics. In the current review, their potential in the immunomodulation of immune cells and their use as immune stimulatory molecules to elicit specific cytotoxic responses against the tumor are discussed.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_39 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	1
title_short	Clinical Implementation of MicroRNAs in Cancer Immunology
url	https://doi.org/10.3390/ijtm4010003 https://doaj.org/article/c06fc88e1ce14363a2cf1ba9caee5d7c https://www.mdpi.com/2673-8937/4/1/3 https://doaj.org/toc/2673-8937
remote_bool	true
ppnlink	178364026X
callnumber-subject	R - General Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.3390/ijtm4010003
callnumber-a	R858-859.7
up_date	2024-07-03T14:59:35.830Z
_version_	1803570407899398144
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ100490840</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414095959.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240414s2024 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/ijtm4010003</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ100490840</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJc06fc88e1ce14363a2cf1ba9caee5d7c</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R858-859.7</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Heidi Schwarzenbach</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Clinical Implementation of MicroRNAs in Cancer Immunology</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2024</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">MicroRNAs (miRNAs), or small non-coding RNAs, modulate the expression of mRNAs and, consequently, a variety of signal transduction pathways. Due to their dysregulation in cancer, they exert oncogenic pressure and have an impact on the immune system with their protective functions. These immunosuppressive characteristics of miRNAs in cancer promote cancer progression and metastasis, causing the dysregulation of immune cells and the immune escape of tumor cells. In contrast, there are also tumor suppressor miRNAs that are able to activate the immune system. Therefore, studies on the altered expression of miRNAs that consider both the oncogenic and tumor-suppressive aspects of miRNAs have become an important research field for advancing immunotherapeutic interventions using miRNAs or their inhibitors as therapeutics. In the current review, their potential in the immunomodulation of immune cells and their use as immune stimulatory molecules to elicit specific cytotoxic responses against the tumor are discussed.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immune system</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">T cells</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">dendritic cells</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">macrophages</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">miRNAs</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">signal transduction pathways</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Computer applications to medicine. Medical informatics</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">International Journal of Translational Medicine</subfield><subfield code="d">MDPI AG, 2021</subfield><subfield code="g">4(2024), 1, Seite 53-71</subfield><subfield code="w">(DE-627)178364026X</subfield><subfield code="x">26738937</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:4</subfield><subfield code="g">year:2024</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:53-71</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/ijtm4010003</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/c06fc88e1ce14363a2cf1ba9caee5d7c</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2673-8937/4/1/3</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2673-8937</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">4</subfield><subfield code="j">2024</subfield><subfield code="e">1</subfield><subfield code="h">53-71</subfield></datafield></record></collection>
score	7.400613

Nicht das Richtige dabei?

Schreiben Sie uns!

Clinical Implementation of MicroRNAs in Cancer Immunology

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?